Finerenone manufacturers
- Finerenone
-
- $0.00 / 25kg
-
2024-06-12
- CAS:1050477-31-0
- Min. Order: 1kg
- Purity: ＞99% by HPLC
- Supply Ability: 10kg/month
- Finerenone
-
- $0.00 / 25kg
-
2024-06-06
- CAS:1050477-31-0
- Min. Order: 1kg
- Purity: 98% HPLC
- Supply Ability: 100 kgs
- Finerenone
-
- $0.00 / 1kg
-
2024-05-24
- CAS:1050477-31-0
- Min. Order: 0.1kg
- Purity: 98%
- Supply Ability: 100kg
|
| | Finerenone Basic information |
| Product Name: | Finerenone | | Synonyms: | Finerenone (BAY 94-8862);BAY948862;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;BAY 94-8862;Finerone;Mr Neri ketone;(S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide | | CAS: | 1050477-31-0 | | MF: | C21H22N4O3 | | MW: | 378.42 | | EINECS: | | | Product Categories: | chemical;1050477-31-0;API;1 | | Mol File: | 1050477-31-0.mol |  |
| | Finerenone Chemical Properties |
| Boiling point | 554.7±50.0 °C(Predicted) | | density | 1.29±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMF: 10 mg/ml DMSO: 3 mg/ml Ethanol: insol PBS (pH 7.2): insol | | pka | 14.76±0.40(Predicted) | | form | solid | | λmax | 255 nm | | InChI | InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1 | | InChIKey | BTBHLEZXCOBLCY-QGZVFWFLSA-N | | SMILES | N1C2=C(C(OCC)=NC=C2C)[C@H](C2=CC=C(C#N)C=C2OC)C(C(N)=O)=C1C |
| | Finerenone Usage And Synthesis |
| Description | Finerenone is a novel mineralocorticoid receptor antagonist that has the effect of delaying the progression of chronic kidney disease. Some people may be aware of two other mineralocorticoid receptor antagonists: the diuretic antihypertensive drug spironolactone, and eplerenone.Finerenone is their cognate derivative and is a third-generation mineralocorticoid receptor antagonist. So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. Finerenone was granted FDA approval on 9 July 2021, followed by the EMA approval on 11 March 2022. | | Uses | Finerenone is the first non-steroidal selective mineralocorticoid receptor antagonist, which can be used for the treatment of diabetic nephropathy, chronic kidney disease and end-stage renal disease. It can reduce the proteinuria of patients and improve the glomerular filtration rate. | | Brand name | Finerenone is sold under the brand name Kerendia and Firialta. | | Biological Activity | Finerenone (FIN, BAY 94-8862) is a highly selective, orally active, nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential to study cardio-renal diseases such as type 2 diabetes and chronic kidney disease. | | in vivo | Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat. | | Mode of action | Finerenone is a Nonsteroidal Mineralocorticoid-Receptor Antagonist. The mechanism of action of finerenone is as a Mineralocorticoid Receptor Antagonist. Finerenone inhibits the effects of mineralocorticoids like aldosterone and cortisol when the MR is overactivated, possibly reducing inflammation and fibrosis in the heart and kidney. | | References | Kolkhof, P., Hartmann, E., Freyberger, A., et al.Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
DOI: 10.1159/000516213
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. |
| | Finerenone Preparation Products And Raw materials |
|